Lab 21 has sold its blood bank screening business to Trinity Biotech for $7.5 million. Backed by healthcare entrepreneur and investor Professor Sir Christopher Evans OBE PhD’s Excalibur Group, Lab 21 is a medicine diagnostic specialist supporting healthcare providers, the pharmaceutical and biotechnology industries with technically advanced products and services. Livingstone advised on the transaction.
Livingstone’s Healthcare sector team has advised Lab 21 Ltd on the sale of its blood bank screening business to Trinity Biotech plc, for US$7.5m.
Backed by high-profile healthcare entrepreneur and investor Professor Sir Christopher Evans OBE PhD’s Excalibur Group, Lab 21 is a personalised medicine diagnostic specialist supporting healthcare providers, the pharmaceutical and biotechnology industries with technically advanced products and services.
The blood bank screening business acquired by Trinity sells best-in-class products for screening for syphilis and malaria; the syphilis product enjoys 75% market share in blood bank markets in the UK, France, Germany, the Netherlands, Switzerland, Austria and Belgium.
Due to funding difficulties in Lab 21, the company asked Livingstone to explore strategic options. Working closely with their Debt Advisory colleagues, Livingstone’s Healthcare team concluding that the sale of the blood bank screening business offered the best way to bring additional liquidity in to Lab 21, while allowing it to focus on the opportunities in the higher-growth personalised medicine segment through its specialism in companion diagnostics.
Kevin Tansley, Trinity’s CFO, explained that “the acquisition of the Lab 21 blood bank business represents a perfect strategic fit for Trinity…To date the Lab 21 business has concentrated on the European blood bank screening market, where through excellent product quality they have taken a dominant share in the larger markets such as the UK, France and Germany. Trinity will concentrate on leveraging this position to enter other markets whilst at the same time targeting the US market through strategic partner relationships. Although Trinity is in no way seeking acquisitions, the Lab 21 opportunity was compelling.”
Daniel Domberger, Director at Livingstone who led the transaction, commented “We are delighted to have helped Lab 21 address its funding difficulties. With its strategic focus now firmly on companion diagnostics and personalised medicine it is in a much stronger position to continue to grow. As Kevin has explained, the strategic fit with Trinity is excellent, and we expect the blood bank screening business to continue to flourish under their ownership.”
Patrick Groarke, Partner at Livingstone, added ”We have known Lab 21′s management team for a long time and thsi successful transaction is another good example of our relationship-led approach.”
Notes to Editors:
About Livingstone Partners LLP
Livingstone is an international mid-market M&A and Debt Advisory firm, with offices in Beijing, Chicago, Düsseldorf, London, and Madrid. Its 70 professional staff complete 50 deals per annum. www.livingstonepartners.com
For further information contact:
Lisa Henshaw, Fourth Day PR
T: +44 (0)20 7403 4411
M: 07985108887 (out-of-office hours)